We aim to make significant advancements to current treatments by listening carefully to the needs of the entire HAE community.
Pharvaris is dedicated to improving the treatment of HAE and the quality of life for people living with HAE through our innovative research, discovery, and development of novel therapeutics. The Pharvaris team is purposeful in its quest to advance new alternatives to injected therapies for all types of HAE and other bradykinin B2-receptor-mediated diseases.
Pharvaris is committed to strong collaboration, closely interacting with patient organizations as well as Experts in the HAE community. Throughout the company we aim to build trust and ongoing dialogue with all members of the community working with and for those with HAE. We are proud to work with the U.S. Hereditary Angioedema Association (HAEA) and HAE International (HAEi) Patient Organizations and support the work that these Organizations undertake on behalf of those living with HAE to support people and their families to build knowledge, awareness, education and further HAE research.
We believe that meaningful interactions and listening closely to the needs of the entire HAE community will unlock key advances in HAE treatment. We aim to make significant advancements to current treatments. By working with the HAE communities, we aim to collaborate to achieve this goal, and further support them to amplify their efforts, educational initiatives, and information to even more people living with HAE. Pharvaris supports the needs of the HAE community to educate professionals and patients to be informed and optimally diagnose and manage their condition.